Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Nov 22;11(11):CD012883.
doi: 10.1002/14651858.CD012883.

18F PET with florbetaben for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)

Gabriel Martínez  1 , Robin Wm Vernooij, Paulina Fuentes Padilla, Javier Zamora, Leon Flicker, Xavier Bonfill Cosp
Affiliations
Review

18F PET with florbetaben for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)

Gabriel Martínez et al. Cochrane Database Syst Rev. .

Abstract

Background: 18F-florbetaben uptake by brain tissue, measured by positron emission tomography (PET), is accepted by regulatory agencies like the Food and Drug Administration (FDA) and the European Medicine Agencies (EMA) for assessing amyloid load in people with dementia. Its added value is mainly demonstrated by excluding Alzheimer's pathology in an established dementia diagnosis. However, the National Institute on Aging and Alzheimer's Association (NIA-AA) revised the diagnostic criteria for Alzheimer's disease and confidence in the diagnosis of mild cognitive impairment (MCI) due to Alzheimer's disease may be increased when using some amyloid biomarkers tests like 18F-florbetaben. These tests, added to the MCI core clinical criteria, might increase the diagnostic test accuracy (DTA) of a testing strategy. However, the DTA of 18F-florbetaben to predict the progression from MCI to Alzheimer's disease dementia (ADD) or other dementias has not yet been systematically evaluated.

Objectives: To determine the DTA of the 18F-florbetaben PET scan for detecting people with MCI at time of performing the test who will clinically progress to ADD, other forms of dementia (non-ADD), or any form of dementia at follow-up.

Search methods: The most recent search for this review was performed in May 2017. We searched MEDLINE (OvidSP), Embase (OvidSP), PsycINFO (OvidSP), BIOSIS Citation Index (Thomson Reuters Web of Science), Web of Science Core Collection, including the Science Citation Index (Thomson Reuters Web of Science) and the Conference Proceedings Citation Index (Thomson Reuters Web of Science), LILACS (BIREME), CINAHL (EBSCOhost), ClinicalTrials.gov (https://clinicaltrials.gov), and the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (http://www.who.int/ictrp/search/en/). We also searched ALOIS, the Cochrane Dementia & Cognitive Improvement Group's specialised register of dementia studies (http://www.medicine.ox.ac.uk/alois/). We checked the reference lists of any relevant studies and systematic reviews, and performed citation tracking using the Science Citation Index to identify any additional relevant studies. No language or date restrictions were applied to electronic searches.

Selection criteria: We included studies that had prospectively defined cohorts with any accepted definition of MCI at time of performing the test and the use of 18F-florbetaben scan to evaluate the DTA of the progression from MCI to ADD or other forms of dementia. In addition, we only selected studies that applied a reference standard for Alzheimer's dementia diagnosis, for example, the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) or Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) criteria.

Data collection and analysis: We screened all titles and abstracts identified in electronic-database searches. Two review authors independently selected studies for inclusion and extracted data to create two-by-two tables, showing the binary test results cross-classified with the binary reference standard. We used these data to calculate sensitivities, specificities, and their 95% confidence intervals. Two independent assessors performed quality assessment using the QUADAS-2 tool plus some additional items to assess the methodological quality of the included studies.

Main results: Progression from MCI to ADD, any other form of dementia, and any form of dementia was evaluated in one study (Ong 2015). It reported data on 45 participants at four years of follow-up; 21 participants met NINCDS-ADRDA criteria for Alzheimer's disease dementia at four years of follow-up, the proportion converting to ADD was 47% of the 45 participants, and 11% of the 45 participants met criteria for other types of dementias (three cases of FrontoTemporal Dementia (FTD), one of Dementia with Lewy body (DLB), and one of Progressive Supranuclear Palsy (PSP)). We considered the study to be at high risk of bias in the domains of the reference standard, flow, and timing (QUADAS-2). MCI to ADD; 18F-florbetaben PET scan analysed visually: the sensitivity was 100% (95% confidence interval (CI) 84% to 100%) and the specificity was 83% (95% CI 63% to 98%) (n = 45, 1 study). Analysed quantitatively: the sensitivity was 100% (95% CI 84% to 100%) and the specificity was 88% (95% CI 68% to 97%) for the diagnosis of ADD at follow-up (n = 45, 1 study). MCI to any other form of dementia (non-ADD); 18F-florbetaben PET scan analysed visually: the sensitivity was 0% (95% CI 0% to 52%) and the specificity was 38% (95% CI 23% to 54%) (n = 45, 1 study). Analysed quantitatively: the sensitivity was 0% (95% CI 0% to 52%) and the specificity was 40% (95% CI 25% to 57%) for the diagnosis of any other form of dementia at follow-up (n = 45, 1 study). MCI to any form of dementia;18F-florbetaben PET scan analysed visually: the sensitivity was 81% (95% CI 61% to 93%) and the specificity was 79% (95% CI 54% to 94%) (n = 45, 1 study). Analysed quantitatively: the sensitivity was 81% (95% CI 61% to 93%) and the specificity was 84% (95% CI 60% to 97%) for the diagnosis of any form of dementia at follow-up (n = 45, 1 study).

Authors' conclusions: Although we were able to calculate one estimation of DTA in, especially, the prediction of progression from MCI to ADD at four years follow-up, the small number of participants implies imprecision of sensitivity and specificity estimates. We cannot make any recommendation regarding the routine use of 18F-florbetaben in clinical practice based on one single study with 45 participants. 18F-florbetaben has high financial costs, therefore, clearly demonstrating its DTA and standardising the process of the 18F-florbetaben modality are important prior to its wider use.

PubMed Disclaimer

Conflict of interest statement

Gabriel Martínez has no known conflicts of interest. Robin WM Vernooij has no known conflicts of interest. Paulina Fuentes Padilla has no known conflicts of interest. Javier Zamora has no known conflicts of interest.

Leon Flicker has no known conflicts of interest. Xavier Bonfill Cosp has no known conflicts of interest.

Figures

1
1
Flow diagram.
2
2
Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study
3
3
Forest plot of tests: 1 18F‐florbetaben visual assessment and progression to ADD, 2 18F‐florbetaben SUVR and progression to ADD, 3 18F‐florbetaben visual assessment and progression to any other form of non‐ADD, 4 18F‐florbetaben SUVR and progression to any other form of non‐ADD, 5 18F‐florbetaben visual assessment and progression to any form of dementia, 6 18F‐florbetaben SUVR and progression to any form of dementia.
1
1. Test
18F‐florbetaben visual assessment and progression to ADD.
2
2. Test
18F‐florbetaben SUVR and progression to ADD.
3
3. Test
18F‐florbetaben visual assessment and progression to any other form of non‐ADD.
4
4. Test
18F‐florbetaben SUVR and progression to any other form of non‐ADD.
5
5. Test
18F‐florbetaben visual assessment and progression to any form of dementia.
6
6. Test
18F‐florbetaben SUVR and progression to any form of dementia.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Ong 2015 {published data only}
    1. Bahar‐Fuchs A, Villemagne V, Ong K, Chetélat G, Lamb F, Reininger CB, et al. Prediction of amyloid‐β pathology in amnestic mild cognitive impairment with neuropsychological tests. Journal of Alzheimer's Disease 2013;33(2):451‐62. - PubMed
    1. Ong D, Villemagne V, Bahar‐Fuchs A, Lamb F, Jones G, Reinlinger C, et al. Conversion from mild cognitive impairment to Alzheimer's disease over 12 months: predictive value of AB imaging with 18F‐Florbetaben. Internal Medicine Journal 2011;41 Suppl S3:39.
    1. Ong K, Villemagne V, Bahar‐Fuchs A, Lamb F, Chetelat G, Holl G, et al. Conversion from mild cognitive impairment to Alzheimer's disease over 12 months: predictive value of AB imaging with 18F‐florbetaben. Alzheimer's & Dementia 2011;7 Suppl(4):S217.
    1. Ong K, Villemagne V, Bahar‐Fuchs A, Lamb F, Reininger C, Putz B, et al. Cognitive change and Ab deposition in MCI subjects studied with serial 18F‐florbetaben PET over 2 years. Alzheimer's & Dementia 2012;8 Suppl(4):P22‐3.
    1. Ong K, Villemagne VL, Bahar‐Fuchs A, Lamb F, Jones G, Reininger C, et al. A two‐year longitudinal assessment of abeta deposition in MCI with 18f‐florbetaben. Internal Medicine Journal 2012;42 Suppl S3:12.

References to studies excluded from this review

Kim 2017 {published data only}
    1. Kim HJ, Seo SW, Kim Y, Jang H, Kim KW, Lee JS, et al. Anatomical subtypes of amnestic mild cognitive impairment. Neuro‐degenerative Diseases 2017; Vol. 17, issue Suppl 1:1039.

References to ongoing studies

EUCTR2013‐004671‐12‐BE {unpublished data only}
    1. EUCTR2013‐004671‐12‐BE. Predictive value of biomarkers in patients with amnestic mild cognitive impairment. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2013‐004671‐12‐BE (first received 20 May 2014).
EUCTR2014‐000562‐21‐NL {unpublished data only}
    1. EUCTR2014‐000562‐21‐NL. Amyloid‐PET as a diagnostic marker in daily practice. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2014‐000562‐21‐NL (first received 5 January 2015).
EUCTR2014‐004244‐35‐IT {unpublished data only}
    1. EUCTR2014‐004244‐35‐IT. Amyloid load in prodromal AD with limbic‐predominant phenotype [Amyloid load in prodromal AD with limbic‐predominant phenotype principal investigator ‐ Studio del Carico di Amiloide in AD prodromico con fenotipo limbico]. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2014‐004244‐35‐IT (first received 13 November 2014).
NCT01222351 {unpublished data only}
    1. NCT01222351. Measuring brain amyloid plaque load in older adults using BAY 94‐9172. clinicaltrials.gov/show/NCT01222351 (first received 18 October 2010).
NCT02854033 {unpublished data only}
    1. NCT02854033. Alzheimer's disease neuroimaging initiative 3 (ADNI3) protocol. clinicaltrials.gov/show/NCT02854033 (first received 3 August 2016).

Additional references

Albert 2011
    1. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia 2011;7(3):270‐9. - PMC - PubMed
Alzheimer's Association 2010
    1. Alzheimer's Association. Changing the trajectory of Alzheimer's disease: a national imperative. http://www.alzheimersreadingroom.com/2010/05/changing‐trajectory‐of‐alzh... (accessed prior to 12 October 2017).
APA 1987
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition. Washington, DC: American Psychiatric Association, 1987.
APA 1994
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington, DC: American Psychiatric Association, 1994.
Archer 2015
    1. Archer HA, Smailagic N, John C, Holmes RB, Takwoingi Y, Coulthard EJ, et al. Regional Cerebral Blood Flow Single Photon Emission Computed Tomography for detection of Frontotemporal dementia in people with suspected dementia. Cochrane Database of Systematic Reviews 2015, Issue 6. [DOI: 10.1002/14651858.CD010896.pub2] - DOI - PMC - PubMed
Arevalo‐Rodriguez 2015
    1. Arevalo‐Rodriguez I, Smailagic N, Figuls MRI, Ciapponi A, Sanchez‐Perez E, Giannakou A, et al. Mini‐Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI). Cochrane Database of Systematic Reviews 2015, Issue 3. [DOI: 10.1002/14651858.CD010783.pub2] - DOI - PMC - PubMed
Barthel 2011
    1. Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, et al. Cerebral amyloid‐β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet. Neurology 2011;10(5):424‐35. - PubMed
Bossuyt 2008
    1. Bossuyt PM, Leeflang MM. Chapter 6: Developing criteria for including studies. In: Deeks JJ, Bossuyt PM, Gatsonis C, editor(s). Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 1.0.0. The Cochrane Collaboration, 2013. Available from srdta.cochrane.org.
Boxer 2005
    1. Boxer AL, Miller BL. Clinical features of frontotemporal dementia. Alzheimer Disease and Associated Disorders 2005;19(Suppl 1):S3‐6. - PubMed
Brun 1994
    1. Brun A, Englund B, Gustafson L, Passant U, Mann DMA, Neary D, et al. Clinical and neuropathological criteria for frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry 1994;57(4):416‐8. - PMC - PubMed
Bruscoli 2004
    1. Bruscoli M, Lovestone S. Is MCI really just early dementia? A systematic review of conversion studies. International Psychogeriatrics 2004;16(2):129‐40. - PubMed
Chan 2014
    1. Chan CCH, Fage BA, Smailagic N, Gill SS, Herrmann N, Nikolaou V, et al. Mini‐Cog for the diagnosis of Alzheimer’s disease dementia and other dementias within a secondary care setting. Cochrane Database of Systematic Reviews 2014, Issue 12. [DOI: 10.1002/14651858.CD011414] - DOI - PMC - PubMed
CMS 2013
    1. The Centers for Medicare & Medicaid Services. Decision memo for beta amyloid positron emission tomography in dementia and neurodegenerative disease (CAG‐00431N). cms.gov/medicare‐coverage‐database/details/nca‐decision‐memo.aspx?NCAId=265 (accessed 08 October 2015).
Cordella 2013
    1. Cordella CB, Borson S, Boustani M, Chodosh J, Reuben D, Verghese J, et al. Alzheimer's Association recommendations for operationalizing the detection of cognitive impairment during the Medicare Annual Wellness Visit in a primary care setting. Alzheimer's & Dementia 2013;9(2):141‐50. - PubMed
Creavin 2016
    1. Creavin S, Wisniewski S, Noel‐Storr A, Trevelyan C, Hampton T, Rayment D, et al. Mini‐Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations. Cochrane Database of Systematic Reviews 2016, Issue 4. [DOI: 10.1002/14651858.CD011145.pub2] - DOI - PMC - PubMed
Davis 2013
    1. Davis DHJ, Creavin ST, Noel‐Storr A, Quinn TJ, Smailagic N, Hyde C, et al. Neuropsychological tests for the diagnosis of Alzheimer’s disease dementia and other dementias: a generic protocol for cross‐sectional and delayed‐verification studies. Cochrane Database of Systematic Reviews 2013, Issue 3. [DOI: 10.1002/14651858.CD010460] - DOI - PMC - PubMed
Davis 2015
    1. Davis DHJ, Creavin ST, Yip JLY, Noel‐Storr AH, Brayne C, Cullum S. Montreal Cognitive Assessment for the diagnosis of Alzheimer’s disease and other dementias. Cochrane Database of Systematic Reviews 2015, Issue 10. [DOI: 10.1002/14651858.CD010775.pub2] - DOI - PMC - PubMed
De la Torre 2004
    1. Torre JC. Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet. Neurology 2004;3(3):184‐90. - PubMed
Dubois 2014
    1. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG‐2 criteria. Lancet. Neurology 2014;13(6):614‐29. - PubMed
Elias‐Sonnenschein 2014a
    1. Elias‐Sonnenschein LS, Viechtbauer W, Ramakers I, Ukoumunne O, Verhey FRJ, Visser PJ. APOE‐ϵ4 allele for the diagnosis of Alzheimer's and other dementia disorders in people with mild cognitive impairment in a community setting. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD010948] - DOI
Elias‐Sonnenschein 2014b
    1. Elias‐Sonnenschein LS, Viechtbauer W, Ramakers I, Ukoumunne O, Verhey FRJ, Visser PJ. APOE‐ϵ4 allele for the diagnosis of Alzheimer's and other dementia disorders in people with mild cognitive impairment in a primary care setting. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD010949] - DOI
Elias‐Sonnenschein 2014c
    1. Elias‐Sonnenschein LS, Viechtbauer W, Ramakers I, Ukoumunne O, Verhey FRJ, Visser PJ. APOE‐ϵ4 allele for the diagnosis of Alzheimer's and other dementia disorders in people with mild cognitive impairment in a secondary care setting. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD010950] - DOI
EMA 2014
    1. European Medicines Agency. Neuraceq. Annex 1. Summary of product characteristics. www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Product_Information... (accessed 8th April 2015).
Espinosa 2013
    1. Espinosa A, Alegret M, Valero S, Vinyes‐Junque G, Hernandez I, Mauleon A, et al. A longitudinal follow‐up of 550 mild cognitive impairment patients: evidence for large conversion to dementia rates and detection of major risk factors involved. Journal of Alzheimer’s Disease 2013;34(3):769‐80. - PubMed
Fage 2015
    1. Fage BA, Chan CCH, Gill SS, Noel‐Storr AH, Herrmann N, Smailagic N, et al. Mini‐Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a community setting. Cochrane Database of Systematic Reviews 2015, Issue 2. [DOI: 10.1002/14651858.CD010860.pub2] - DOI - PubMed
FDA 2014
    1. Food, Drug Administration. Neuroceq. www.accessdata.fda.gov/drugsatfda_docs/label/2014/204677s000lbl.pdf (accessed 08/04/2015).
Filippini 2012
    1. Filippini G, Casazza G, Bellatorre AG, Lista C, Duca P, Beecher D, et al. The role of MRI in the early diagnosis of Alzheimer’s disease or other dementias in persons with mild cognitive impairment (MCI). Cochrane Database of Systematic Reviews 2012, Issue 2. [DOI: 10.1002/14651858.CD009628] - DOI
Garcia‐Alloza 2011
    1. Garcia‐Alloza M, Gregory J, Kuchibhotla KV, Fine S, Wei Y, Ayata C, et al. Cerebrovascular lesions induce transient β‐amyloid deposition. Brain 2011;134(12):3697‐707. - PMC - PubMed
Geslani 2005
    1. Geslani DM, Tierney MC, Herrmann N, Szalai JP. Mild cognitive impairment: an operational definition and its conversion rate to Alzheimer’s disease. Dementia and Geriatric Cognitive Disorders 2005;19(5‐6):383‐9. - PubMed
Goedert 2006
    1. Goedert M, Spillantini MG. A century of Alzheimer's disease. Science 2006;314(5800):777‐81. - PubMed
Harrison 2014
    1. Harrison JK, Fearon P, Noel‐Storr AH, McShane R, Stott DJ, Quinn TJ. Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within a general practice (primary care) setting. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD010771.pub2] - DOI - PubMed
Harrison 2015
    1. Harrison JK, Fearon P, Noel‐Storr AH, McShane R, Stott DJ, Quinn TJ. Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within a secondary care setting. Cochrane Database of Systematic Reviews 2015, Issue 3. [DOI: 10.1002/14651858.CD010772.pub2] - DOI - PubMed
Hauw 1994
    1. Hauw JJ, Daniel SE, Dickson D, Horoupian DS, Jellinger K, Lantos PL, et al. Preliminary NINDS neuropathologic criteria for Steele‐Richardson‐Olszewski syndrome (progressive supranuclear palsy). Neurology 1994;44(11):2015‐9. - PubMed
Hendry 2014
    1. Hendry K, Lees RA, McShane R, Noel‐Storr AH, Stott DJ, Quinn TJ. AD‐8 for diagnosis of dementia across a variety of healthcare settings. Cochrane Database of Systematic Reviews 2014, Issue 5. [DOI: 10.1002/14651858.CD011121] - DOI - PMC - PubMed
Herscovitch 2015
    1. Herscovitch P. Regulatory approval and insurance reimbursement: the final steps in clinical translation of amyloid brain imaging. Clinical and Translational Imaging 2015;3:75‐7.
Heyden 2013
    1. Hayden EY, Teplow DB. Amyloid β‐protein oligomers and Alzheimer’s disease. Alzheimer's Research & Therapy 2013;5(6):1‐11. - PMC - PubMed
Hyman 2012
    1. Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging‐Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimer's & Dementia 2012;8(1):1‐13. - PMC - PubMed
ICD‐10
    1. World Health Organization. International statistical Classification of Diseases and related health problems (ICD‐10 Version 2010). apps.who.int/classifications/icd10/browse/2010/en (accessed 29 January 2015).
Jack 2010
    1. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet. Neurology 2010;9(1):119‐28. - PMC - PubMed
Jellinger 2006
    1. Jellinger K. Clinicopathological analysis of dementia disorders in the elderly ‐ an update. Journal of Alzheimer's Disease 2006;9(Supplement 3):61‐70. - PubMed
Johnson 2013
    1. Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Journal of Nuclear Medicine 2013;54(3):476‐90. - PubMed
Knottnerus 2002
    1. Knottnerus JA, Weel C, Muris JW. Evaluation of diagnostic procedures. BMJ 2002;324(7335):477‐80. - PMC - PubMed
Kokkinou 2014
    1. Kokkinou M, Smailagic N, Noel‐Storr AH, Hyde C, Ukoumunne O, Worrall RE, et al. Plasma and Cerebrospinal fluid (CSF) Abeta42 for the differential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care setting. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD010945] - DOI - PMC - PubMed
Lees 2014
    1. Lees RA, Stott DJ, McShane R, Noel‐Storr AH, Quinn TJ. Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the early diagnosis of dementia across a variety of healthcare settings. Cochrane Database of Systematic Reviews 2014, Issue 10. [DOI: 10.1002/14651858.CD011333] - DOI - PMC - PubMed
Lijmer 1999
    1. Lijmer JG, Mol BW, Heisterkamp S, Bonsel GJ, Prins MH, Meulen JH, et al. Empirical evidence of design‐related bias in studies of diagnostic tests. JAMA 1999;282(11):1061‐6. - PubMed
Lundh 2017
    1. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2017, Issue 2. [DOI: 10.1002/14651858.MR000033.pub2] - DOI - PMC - PubMed
Ma 2014
    1. Ma Y, Zhang S, Li J, Zheng DM, Guo Y, Feng J, et al. Predictive accuracy of amyloid imaging for progression from mild cognitive impairment to Alzheimer disease with different lengths of follow‐up: a meta‐analysis. Medicine 2014;93(27):1‐12. - PMC - PubMed
Martínez 2016
    1. Martínez G, Flicker L, Vernooij RWM, Fuentes Padilla P, Zamora J, Figuls MRI, et al. 18F PET ligands for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database of Systematic Reviews 2016, Issue 5. [DOI: 10.1002/14651858.CD012216] - DOI
Matthews 2008
    1. Matthews FE, Stephan BC, McKeith IG, Bond J, Brayne C, Medical Research Council Cognitive Function and Ageing Study. Two‐year progression from mild cognitive impairment to dementia: to what extent do different definitions agree?. Journal of the American Geriatrics Society 2008;56(8):1424‐33. - PubMed
Mattsson 2009
    1. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009;302(4):385‐93. - PubMed
McCleery 2015
    1. McCleery J, Morgan S, Bradley KM, Noel‐Storr AH, Ansorge O, Hyde C. Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies. Cochrane Database of Systematic Reviews 2015, Issue 1. [DOI: 10.1002/14651858.CD010633.pub2] - DOI - PMC - PubMed
McKeith 1996
    1. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47(5):1113‐24. - PubMed
McKeith 2005
    1. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 2005;65(12):1863‐72. - PubMed
McKhann 1984
    1. McKhann GM, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS‐ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34(7):939‐44. - PubMed
McKhann 2011
    1. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia 2011;7(3):263‐9. - PMC - PubMed
Mitchell 2009
    1. Mitchell AJ, Shiri‐Feshki M. Rate of progression of mild cognitive impairment to dementia ‐ meta‐analysis of 41 robust inception cohort studies. Acta Psychiatrica Scandinavica 2009;119(4):252‐65. - PubMed
Morris 1993
    1. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43(11):2412‐4. - PubMed
NAO 2007
    1. National Audit Office. Improving services and support for people with dementia. Report by the Comptroller and Auditor General. HC 604 Session General 2006‐2007. www.nao.org.uk/wp‐content/uploads/2007/07/0607604.pdf (accessed 25th March 2015).
Neary 1998
    1. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51(6):1546‐54. - PubMed
NICE 2006
    1. National Institute for Health Care Excellence. Dementia: supporting people with dementia and their carers in health and social care. NICE guidelines [CG42]. www.nice.org.uk/guidance/cg42 (accessed 17th April 2015).
Noel‐Storr 2013
    1. Noel‐Storr AH, Flicker L, Ritchie CW, Nguyen GH, Gupta T, Wood P, et al. Systematic review of the body of evidence for the use of biomarkers in the diagnosis of dementia. Alzheimer's & Dementia 2013;9(3):e96‐105. - PubMed
Noel‐Storr 2014
    1. Noel‐Storr AH, McCleery JM, Richard E, Ritchie CW, Flicker L, Cullum SJ, et al. Reporting standards for studies of diagnostic test accuracy in dementia: the STARDdem Initiative. Neurology 2014;83(4):364‐73. - PMC - PubMed
Okello 2007
    1. Okello A, Edison P, Archer H, Hinz R, Fox N, Kennedy AM, et al. Amyloid deposition and cerebral glucose metabolism in mild cognitive impairment: a longitudinal 11C‐PIB and 18F‐FDG PET Study. Journal of Neurology, Neurosurgery and Psychiatry 2007;78(2):219‐20.
Petersen 1999
    1. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology 1999;56(3):303‐8. - PubMed
Petersen 2004
    1. Petersen RC. Mild cognitive impairment as a diagnostic entity. Journal of Internal Medicine 2004;256(3):183‐94. - PubMed
Petersen 2009
    1. Petersen RC, Roberts RO, Knopman DS, Boeve BF, Geda YE, Ivnik RJ, et al. Mild cognitive impairment: ten years later. Archives of Neurology 2009;66(12):1447‐55. - PMC - PubMed
Quinn 2014
    1. Quinn TJ, Fearon P, Noel‐Storr AH, Young C, McShane R, Stott DJ. Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within community dwelling populations. Cochrane Database of Systematic Reviews 2014, Issue 4. [DOI: 10.1002/14651858.CD010079.pub2] - DOI - PubMed
Rascovsky 2011
    1. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011;134(Pt 9):2456‐77. - PMC - PubMed
Review Manager 2014 [Computer program]
    1. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Richard 2012
    1. Richard E, Schmand B, Eikelenboom P, Westendorp RG, Gool WA. The Alzheimer myth and biomarker research in dementia. Journal of Alzheimer's Disease 2012;31(Suppl 3):S203‐9. - PubMed
Ritchie 2013
    1. Ritchie C, Smailagic N, Ladds EC, Noel‐Storr AH, Ukoumunne O, Martin S. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database of Systematic Reviews 2013, Issue 10. [DOI: 10.1002/14651858.CD010803] - DOI - PMC - PubMed
Ritchie 2014
    1. Ritchie C, Smailagic N, Noel‐Storr AH, Takwoingi Y, Flicker L, Mason SE, et al. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database of Systematic Reviews 2014, Issue 6. [DOI: 10.1002/14651858.CD008782.pub4] - DOI - PMC - PubMed
Román 1993
    1. Román GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS‐AIREN International Workshop. Neurology 1993;43(2):250‐60. - PubMed
Royall 2014
    1. Royall DR, Palmer RF. The temporospatial evolution of neuritic plaque‐related and independent tauopathies: implications for dementia staging. Journal of Alzheimer’s Disease 2014;40(3):541‐9. - PMC - PubMed
Sabbagh 2017
    1. Sabbagh MN, Schäuble B, Anand K, Richards D, Murayama S, Akatsu H, et al. Histopathology and florbetaben PET in patients incorrectly diagnosed with Alzheimer's disease.. Journal of Alzheimer's Disease 2017;56(2):441‐46. - PubMed
Sabri 2015
    1. Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study. Alzheimer's & Dementia 2015;11(8):964‐74. - PubMed
Savva 2009
    1. Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C, Medical Research Council Cognitive Function and Ageing Study. Age, neuropathology, and dementia. New England Journal of Medicine 2009;360(22):2302‐9. - PubMed
Schneider 2007
    1. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community‐dwelling older persons. Neurology 2007;69(24):2197‐204. - PubMed
Schneider 2009
    1. Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Annals of Neurology 2009;66(2):200‐8. - PMC - PubMed
Seitz 2014
    1. Seitz DP, Fage BA, Chan CCH, Gill SS, Herrmann N, Smailagic N, et al. Mini‐Cog for the diagnosis of Alzheimer’s disease dementia and other dementias within a primary care setting. Cochrane Database of Systematic Reviews 2014, Issue 12. [DOI: 10.1002/14651858.CD011415] - DOI - PMC - PubMed
Selkoe 2016
    1. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. European Molecular Biology Organization 2016;8(6):595‐608. - PMC - PubMed
Serrano‐Pozo 2013
    1. Serrano‐Pozo A, Qian J, Monsell SE, Frosch MP, Betensky RA, Hyman BT. Examination of the clinicopathologic continuum of Alzheimer disease in the autopsy cohort of the National Alzheimer Coordinating Center. Journal of Neuropathology and Experimental Neurology 2013;72(12):1182‐92. - PMC - PubMed
Smailagic 2015
    1. Smailagic N, Vacante M, Hyde C, Martin S, Ukoumunne O, Sachpekidis C. 18F‐FDG PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database of Systematic Reviews 2015, Issue 1. [DOI: 10.1002/14651858.CD010632.pub2] - DOI - PMC - PubMed
Sperling 2011
    1. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia 2011;7(3):280‐92. - PMC - PubMed
Villemagne 2011
    1. Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, et al. Amyloid imaging with (18)F‐florbetaben in Alzheimer disease and other dementias. Journal of Nuclear Medicine 2011;52(8):1210‐7. - PubMed
Visser 2006
    1. Visser PJ, Kester A, Jolles J, Verhey F. Ten‐year risk of dementia in subjects with mild cognitive impairment. Neurology 2006;67(7):1201‐7. - PubMed
White 2009
    1. White L. Brain lesions at autopsy in older Japanese‐American men as related to cognitive impairment and dementia in the final years of life: a summary report from the Honolulu‐Asia aging study. Journal of Alzheimer's Disease 2009;18(3):713‐25. - PubMed
Whiting 2011
    1. Whiting PF, Rutjes AWS, Westwood ME, Mallet S, Deeks JJ, Reitsma JB. QUADAS‐2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal Medicine 2011;155(8):529‐36. - PubMed
WHO 2012
    1. World Health Organization, Alzheimer's Disease International. Dementia: a public health priority. www.who.int/mental_health/publications/dementia_report_2012/en/ (accessed 23th September 2015).
Winblad 2004
    1. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, et al. Mild cognitive impairment ‐ beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. Journal of Internal Medicine 2004;256(3):240‐6. - PubMed
Zhang 2005
    1. Zhang W, Oya S, Kung MP, Hou C, Maier DL, Kung HF. F‐18 Polyethyleneglycol stilbenes as PET imaging agents targeting Abeta aggregates in the brain. Nuclear Medicine and Biology 2005;32(8):799‐809. - PubMed
Zhang 2014
    1. Zhang S, Smailagic N, Hyde C, Noel‐Storr AH, Takwoingi Y, McShane R, et al. 11C‐PIB‐PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD010386.pub2] - DOI - PMC - PubMed

Publication types

LinkOut - more resources